Becton Dickinson (BD) will invest $3 billion (£2.46 billion) to expand US manufacturing of essential medical products, including needles, President Donald Trump announced on Monday, with more than $1 billion (£753.8 million) earmarked for Nebraska.

BD later confirmed the agreement. The company said the $3 billion (£2.46 billion) forms part of a $19 billion (£15.58 billion) US investment plan, developed in partnership with the US government, that will run over several years and cover capital, operational and supply chain spending.

It said the manufacturing expansion would add about 5 billion medical consumables to its annual US output and raise its share of domestically supplied essential medical consumables to roughly 80 per cent.

Announcing the plan in a post on Truth Social, Mr Trump credited his 'strong Medical Device TARIFFS', which he said would be in place by the end of the year. BD had not immediately responded to requests for comment when the post appeared, according to Reuters.

Trump Hails Major Nebraska Manufacturing Boost

Mr Trump said the Nebraska funding would increase production of syringes, needles and other medical products, including needles made with American steel.

The White House separately said BD was investing $110 million (£90.2 million) to expand prefillable syringe production at its plant in Columbus, Nebraska, creating about 120 jobs. That follows an earlier $35 million (£28.7 million) investment at the site. BD said in January that it planned the $110 million (£90.2 million) expansion. It was not clear whether that sum forms part of the $3 billion (£2.46 billion).

Read more

Tariffs at the Heart of Onshoring Drive

The announcement fits Mr Trump's push to bring healthcare manufacturing back to the United States.

He has argued that the country remains exposed to overseas supply chains for basic medical equipment, years after the shortages seen during the Covid-19 pandemic. His administration has pressed companies to move production of items such as syringes and protective gear into American plants.

Mr Trump has presented the planned duties as a way to tilt the economics in favour of building in the US rather than buying cheaply from abroad. Any new Section 232 duties resulting from the investigation had not yet been announced.

The Commerce Department opened a Section 232 investigation into imports of personal protective equipment, medical consumables and medical equipment, including devices, in September 2025. The investigation could lead to additional tariffs or other measures, but no final tariff rate or product list has been published.

For importers, those details will determine which medical devices and components face additional costs at the US border. Higher landed costs could force companies to absorb the expense, pass it on to customers or shift sourcing and production.

BD Bets Big on US Growth

BD shares closed 2.19 per cent higher at $180.67 (£148.15) on Monday. The gain came before Mr Trump's announcement and so cannot be attributed to the $3 billion (£2.46 billion) deal.

BD is one of the world's largest medical technology companies, supplying the needles, syringes and laboratory kits used in vaccination campaigns and routine blood tests. In February it completed the separation of its Biosciences and Diagnostic Solutions business, which was combined with Waters Corporation, leaving a more tightly focused company.

In August, BD reported fiscal third-quarter revenue of $5 billion (£4.10 billion), up 5.4 per cent year on year, with adjusted diluted earnings per share of $3.23 (£2.65). The company raised the midpoint of its earnings outlook and said it expected full-year revenue growth towards the top of its guidance range.

Read more